Crystal Structure of CD27 in Complex with a Neutralizing Noncompeting Antibody

Overview

Journal Acta Crystallogr F Struct Biol Commun

Specialty Chemistry

Date 2017 May 5

PMID 28471362

Citations 5

Authors

Alexey Teplyakov

Galina Obmolova

Thomas J Malia

Gary L Gilliland

Affiliations

Soon will be listed here.

Abstract

CD27 is a T-cell and B-cell co-stimulatory glycoprotein of the tumor necrosis factor (TNF) receptor superfamily that is dependent on the availability of the TNF-like ligand CD70. Therapeutic approaches to treating autoimmune diseases and cancers with antagonistic and agonistic anti-CD27 monoclonal antibodies (mAbs), respectively, have recently been developed. Mouse anti-human CD27 mAb 2177 shows potency in neutralizing CD70-induced signaling; however, it does not block the binding of soluble CD70. To provide insight into the mechanism of action of the mAb, the crystal structure of the CD27 extracellular domain in complex with the Fab fragment of mAb 2177 was determined at 1.8 Å resolution. CD27 exhibits the assembly of cysteine-rich domains characteristic of the TNF receptor superfamily. The structure reveals a unique binding site of mAb 2177 at the edge of the receptor molecule, which allows the mAb to sterically block the cell-bound form of CD70 from reaching CD27 while leaving the ligand epitope clear. This mode of action suggests a potential dual use of mAb 2177 either as an antagonist or as an agonist.

Citing Articles

CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells.

Trac N, Oh H, Jones L, Caliliw R, Ohtake S, Shuch B Molecules. 2022; 27(23).

PMID: 36500549 PMC: 9738223. DOI: 10.3390/molecules27238457.

Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia.

Leick M, Silva H, Scarfo I, Larson R, Choi B, Bouffard A Cancer Cell. 2022; 40(5):494-508.e5.

PMID: 35452603 PMC: 9107929. DOI: 10.1016/j.ccell.2022.04.001.

Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering.

Heckel F, Turaj A, Fisher H, Chan H, Marshall M, Dadas O Commun Biol. 2022; 5(1):229.

PMID: 35288635 PMC: 8921514. DOI: 10.1038/s42003-022-03182-6.

Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency.

Ghosh S, Bal S, Edwards E, Pillay B, Heredia R, Cipe F Blood. 2020; 136(23):2638-2655.

PMID: 32603431 PMC: 7735164. DOI: 10.1182/blood.2020006738.

SEPPA 3.0-enhanced spatial epitope prediction enabling glycoprotein antigens.

Zhou C, Chen Z, Zhang L, Yan D, Mao T, Tang K Nucleic Acids Res. 2019; 47(W1):W388-W394.

PMID: 31114919 PMC: 6602482. DOI: 10.1093/nar/gkz413.

References

Wajant H . Therapeutic targeting of CD70 and CD27. Expert Opin Ther Targets. 2016; 20(8):959-73. DOI: 10.1517/14728222.2016.1158812. View

Chan F, Chun H, Zheng L, Siegel R, Bui K, Lenardo M . A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science. 2000; 288(5475):2351-4. DOI: 10.1126/science.288.5475.2351. View

Zhao Y, Gutshall L, Jiang H, Baker A, Beil E, Obmolova G . Two routes for production and purification of Fab fragments in biopharmaceutical discovery research: Papain digestion of mAb and transient expression in mammalian cells. Protein Expr Purif. 2009; 67(2):182-9. DOI: 10.1016/j.pep.2009.04.012. View

Alkhairy O, Perez-Becker R, Driessen G, Abolhassani H, van Montfrans J, Borte S . Novel mutations in TNFRSF7/CD27: Clinical, immunologic, and genetic characterization of human CD27 deficiency. J Allergy Clin Immunol. 2015; 136(3):703-712.e10. DOI: 10.1016/j.jaci.2015.02.022. View

Denoeud J, Moser M . Role of CD27/CD70 pathway of activation in immunity and tolerance. J Leukoc Biol. 2010; 89(2):195-203. DOI: 10.1189/jlb.0610351. View

Obmolova G, Malia T, Teplyakov A, Sweet R, Gilliland G . Promoting crystallization of antibody-antigen complexes via microseed matrix screening. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 8):927-33. PMC: 2917276. DOI: 10.1107/S0907444910026041. View

Liu C, Walter T, Huang P, Zhang S, Zhu X, Wu Y . Structural and functional insights of RANKL-RANK interaction and signaling. J Immunol. 2010; 184(12):6910-9. DOI: 10.4049/jimmunol.0904033. View

Borst J, Hendriks J, Xiao Y . CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol. 2005; 17(3):275-81. DOI: 10.1016/j.coi.2005.04.004. View

Kabsch W . XDS. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 2):125-32. PMC: 2815665. DOI: 10.1107/S0907444909047337. View

10.

Mongkolsapaya J, Grimes J, Chen N, Xu X, Stuart D, Jones E . Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol. 1999; 6(11):1048-53. DOI: 10.1038/14935. View

11.

Naismith J, Devine T, Kohno T, Sprang S . Structures of the extracellular domain of the type I tumor necrosis factor receptor. Structure. 1996; 4(11):1251-62. DOI: 10.1016/s0969-2126(96)00134-7. View

12.

Yamamoto H, Kishimoto T, Minamoto S . NF-kappaB activation in CD27 signaling: involvement of TNF receptor-associated factors in its signaling and identification of functional region of CD27. J Immunol. 1998; 161(9):4753-9. View

13.

Li B, Russell S, Compaan D, Totpal K, Marsters S, Ashkenazi A . Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antibody agonists. J Mol Biol. 2006; 361(3):522-36. DOI: 10.1016/j.jmb.2006.06.042. View

14.

Graves J, Kordich J, Huang T, Piasecki J, Bush T, Sullivan T . Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity. Cancer Cell. 2014; 26(2):177-89. DOI: 10.1016/j.ccr.2014.04.028. View

15.

Wyzgol A, Muller N, Fick A, Munkel S, Grigoleit G, Pfizenmaier K . Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J Immunol. 2009; 183(3):1851-61. DOI: 10.4049/jimmunol.0802597. View

16.

Hintzen R, van Lier R, Kuijpers K, Baars P, Schaasberg W, Lucas C . Elevated levels of a soluble form of the T cell activation antigen CD27 in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 1991; 35(1-3):211-7. DOI: 10.1016/0165-5728(91)90175-7. View

17.

van Montfrans J, Hoepelman A, Otto S, van Gijn M, van de Corput L, de Weger R . CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia. J Allergy Clin Immunol. 2011; 129(3):787-793.e6. PMC: 3294016. DOI: 10.1016/j.jaci.2011.11.013. View

18.

Tak P, Hintzen R, Teunissen J, Smeets T, Daha M, van Lier R . Expression of the activation antigen CD27 in rheumatoid arthritis. Clin Immunol Immunopathol. 1996; 80(2):129-38. DOI: 10.1006/clin.1996.0106. View

19.

Camerini D, Walz G, Loenen W, Borst J, Seed B . The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family. J Immunol. 1991; 147(9):3165-9. View

20.

Naismith J, Sprang S . Modularity in the TNF-receptor family. Trends Biochem Sci. 1998; 23(2):74-9. DOI: 10.1016/s0968-0004(97)01164-x. View